Clinical Report: Evaluating Anti-HER2 Therapy in Uncommon Cancers

Overview

Expand on the implications of the findings in the context of existing HER2-targeted therapy literature.

Background

HER2-targeted therapies have shown success in common cancers, yet their role in rare tumors remains underexplored. The identification of ERBB2 gene amplification through next-generation sequencing (NGS) may provide a more accurate predictor of treatment response than traditional immunohistochemistry (IHC) methods. This case series aims to shed light on the therapeutic potential of anti-HER2 agents in rare malignancies, where treatment options are often limited.

Data Highlights

Key Findings

• All patients with ERBB2-amplified rare tumors achieved meaningful objective responses to anti-HER2 therapies.
• High-level gene amplification can predict ADC efficacy regardless of IHC status.
• Trastuzumab deruxtecan (T-DXd) shows promise in HER2-low disease, expanding treatment options.
• Integration of NGS into diagnostic workflows can identify potential responders among rare tumors.
• Sequential therapy with T-DXd and T-DM1 was effective in managing treatment-limiting toxicities.

Clinical Implications

The findings suggest that HER2-targeted therapies can be effective in rare tumors with ERBB2 amplification, warranting consideration in treatment planning. Clinicians should incorporate NGS into diagnostic protocols to better identify patients who may benefit from these therapies, even in the absence of strong IHC expression.

Conclusion

This case series underscores the potential of anti-HER2 therapies in treating uncommon cancers, advocating for a shift towards more personalized treatment approaches based on genetic profiling.

References

1. FDA, FDA, 2024 -- FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors
2. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial - PubMed
3. HER2 Protein Overexpression, mRNA Expression, and DNA Amplification Across Solid Tumors: Comparison of Next-Generation Sequencing-Based Assays With Immunohistochemistry - PubMed
4. The ASCO Post — Highlights From the 2021 San Antonio Breast Cancer Symposium Guest Editors
5. The ASCO Post — SIDEBAR: A Tough Call: The T1a HER2-positive Tumor
6. The ASCO Post — Optimizing HER2-directed Therapy in the Clinic
7. The ASCO Post — Complexities of Targeting HER2 in Estrogen Receptor–Positive Breast Cancers
8. Highlights From the 2021 San Antonio Breast Cancer Symposium Guest Editors
9. A Tough Call: The T1a HER2-positive Tumor
10. Optimizing HER2-directed Therapy in the Clinic
11. FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors | FDA
12. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial - PubMed
13. HER2 Protein Overexpression, mRNA Expression, and DNA Amplification Across Solid Tumors: Comparison of Next-Generation Sequencing-Based Assays With Immunohistochemistry - PubMed